News Sentiment

ALT sentiment intelligence

Altimmune Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.87 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-5.9% over one week, +6.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -5.9% Price reacting lower
Trend fit Trend inactive 6.3% over four weeks
Fair value -48.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 36
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 12
Stock Titan 7
simplywall.st 5
www.marketscreener.com 4
Stocktwits 3
Insider Monkey 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 16
Analyst action 7
Regulatory and legal 1
Guidance 1
Balance sheet 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
citybiz Direct company coverage

Altimmune Relocating Headquarters from Maryland to New Jersey

Altimmune, Inc. (NASDAQ: ALT) is moving its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year. This strategic relocation aims to enhance access to biopharmaceutical talent and improve operational efficiencies, positioning the company w

Tone
Positive 70/100
Event
Market update
Published
17 Jun 2026 11:11
Source
citybiz
TradingKey Direct company coverage

Altimmune Inc (ALT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Altimmune Inc's (ALT) dividend and stock split history. It states that the company has not distributed any dividends over the past five years and provides no data on stock splits. The piece presents basic financial information for Altimmune, i

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 06:11
Source
TradingKey
Stock Titan Direct company coverage

Altimmune (ALT) plans New Jersey HQ move with 5-year lease

Altimmune, Inc. (ALT) announced its plans to relocate its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year. The move to the new biopharmaceutical hub is expected to support talent recruitment and achieve long-term cost efficiencies. A

Tone
Positive 61/100
Event
Market update
Published
16 Jun 2026 20:08
Source
Stock Titan
Insider Monkey Direct company coverage

5 Small Cap Stocks with Potential to Rise 1000 Percent

This article highlights Altimmune, Inc. (NASDAQ:ALT) as one of five small-cap stocks with significant growth potential, possibly rising 1000 percent. Altimmune is a late-clinical stage biotechnology company developing pemvidutide for serious liver diseases like MASH, alcohol use

Tone
Positive 74/100
Event
Market update
Published
16 Jun 2026 14:08
Source
Insider Monkey
TradingView Direct company coverage

Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near

Altimmune management outlined their strategy for pemvidutide, their lead metabolic and liver disease drug candidate, at the Goldman Sachs Global Healthcare Conference. The company is primarily focusing on pemvidutide's Phase 3 program for metabolic dysfunction-associated steatohe

Tone
Positive 67/100
Event
Market update
Published
10 Jun 2026 23:40
Source
TradingView